Curis (CRIS) Income from Continuing Operations (2010 - 2026)
Curis (CRIS) reported Income from Continuing Operations of 11442000.0 for Q1 2026, down 7.78% on a YoY basis from 12407382.23 in Q1 2025, and down 159.11% quarter-over-quarter from 19356000.0 in Q4 2025.
Curis (CRIS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Curis has reported Income from Continuing Operations for 17 years, with the latest figure at 11442000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 7.78% year-over-year to 11442000.0; the trailing twelve-month figure through Mar 2026 stood at 8408000.0 (up 80.04% YoY), and the FY2025 full-year result was 7582000.0, up 82.53% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 11442000.0, down from 19356000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 19356000.0 in Q4 2025, with the low at 16109000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 9794000.0 across 5 years, with a median of 11559000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 62.27% — and 2025, when it surged 301.25%.
- Curis' Income from Continuing Operations stood at 11329000.0 in 2022, then declined by 3.38% to 11712000.0 in 2023, then grew by 17.88% to 9618000.0 in 2024, then surged by 301.25% to 19356000.0 in 2025, then sank by 159.11% to 11442000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 11442000.0 (Q1 2026), 19356000.0 (Q4 2025), and 7729000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Curis | 8.58 Mn | -6.42 Mn | - | -11.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.44 Mn |
| Dec 31, 2025 | 19.36 Mn |
| Sep 30, 2025 | -7.73 Mn |
| Jun 30, 2025 | -8.59 Mn |
| Mar 31, 2025 | -10.62 Mn |
| Dec 31, 2024 | -9.62 Mn |
| Sep 30, 2024 | -10.09 Mn |
| Jun 30, 2024 | -11.80 Mn |
| Mar 31, 2024 | -11.88 Mn |
| Dec 31, 2023 | -11.71 Mn |
| Sep 30, 2023 | -12.18 Mn |
| Jun 30, 2023 | -11.96 Mn |
| Mar 31, 2023 | -11.56 Mn |
| Dec 31, 2022 | -11.33 Mn |
| Sep 30, 2022 | -13.29 Mn |
| Jun 30, 2022 | -15.94 Mn |
| Mar 31, 2022 | -16.11 Mn |
| Dec 31, 2021 | -13.62 Mn |
| Sep 30, 2021 | -11.05 Mn |
| Jun 30, 2021 | -11.73 Mn |